All In Biotech

Drug Trial Radar · NCT07894055

A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Different Doses of Adsorbed Acellular Pertussis (Two-component) Diphtheria-tetanus Combined Vaccine (for Adults and Adolescents) in People Aged 10 Years and Older in a Randomized, Blinded, Placebo-controlled Manner

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Sep 25, 2026

Study completion Aug 25, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine

Conditions

  • Pertussis (Whooping Cough)
  • Diphtheria
  • Tetanus

Interventions

  • Tdap vaccineBiological

    intramuscular injection only, and the preferred inoculation site is the deltoid muscle of the upper arm.

  • PlaceboBiological

    intramuscular injection only, and the preferred inoculation site is the deltoid muscle of the upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rates and geometric mean concentration of anti-DT antibodyTime frame: 30 days after injection
  2. Seroconversion rates and geometric mean concentration of anti-TT antibodyTime frame: 30 days after injection
  3. Seroconversion rates and geometric mean concentration of anti-PT antibodyTime frame: 30 days after injection
  4. Seroconversion rates and geometric mean concentration of anti-FHA antibodyTime frame: 30 days after injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ethics Review Committee of Zhejiang Provincial Center for Disease Control

    Lishui, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.